On the stock market since 2017, it operates in the world of health and science. It has 731 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 19% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $42.5M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 14% a year on average.
Over the last 12 months, company executives reported 40 buys and 0 sells. Management buying with its own money is usually read as a good sign.
It pays out $1.98 per share each year — regular cash for whoever holds the stock.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
On our five-subject report card, RHEP sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: RHEP is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.